Durham, North Carolina (April 2, 2026) – KBI Biopharma, a leading global contract development and manufacturing organization (CDMO), has been named Fill-Finish CDMO of the Year and Best in Class for Cultural Fit in the Small/Mid-Sized CDMO Biologic categories at the 2026 CDMO Leadership Awards.
“This recognition matters because it comes directly from customers who have worked side-by-side with us,” said Katie Edgar, Chief Business Officer of KBI Biopharma. “Our commitment to partnership, internally and with strategic partners like Argonaut Manufacturing Services for fill-finish, enables us to deliver best-in-class, end-to-end solutions for our customers. We’ve built a culture around solving complex challenges for patients worldwide, and we thank our customers for trusting us in that mission.”
“We couldn’t be more proud to be KBI’s chosen fill-finish partner,” said Rick Hancock, Chief Executive Officer and Board Member of Argonaut Manufacturing Services. “We have built a deeply collaborative and integrated partnership model with total alignment to our customers’ goals to provide a seamless experience for expert fill-finish services.”
The CDMO Leadership Awards are based on direct feedback from biopharma sponsors who have worked with CDMOs over the past 18–24 months. Recognition reflects verified sponsor evaluations across key performance criteria and minimum qualification thresholds within each category.
“The CDMO Leadership Awards exist to reflect real outsourcing experience, not marketing claims,” said Louis Garguilo, Chief Editor of Outsourced Pharma. “Partnering with Tufts Center for the Study of Drug Development (Tufts CSDD) brings independent academic rigor to survey design, respondent validation, and data analysis, reinforcing the integrity of a program that has long relied on peer feedback from experienced pharma and biotech professionals.”
About KBI Biopharma, Inc.
KBI Biopharma is the CDMO of choice for complex biologics and expert analytics, helping life science companies accelerate the development and manufacture of innovative therapies and vaccines. With deep expertise in mammalian and microbial programs, KBI provides integrated process development, analytical, and cGMP manufacturing services across the drug development lifecycle. KBI’s technologies support more than 250 drug candidates in preclinical and clinical development and 13 marketed products. KBI serves global customers from six locations across the U.S. and Europe.
More information is available at www.kbibiopharma.com.
KBI Biopharma Company Contact
David Self
KBI Biopharma, Inc.
dself@kbibiopharma.com
KBI Biopharma Media Contact
Blair Ciecko
CG Life
bciecko@cglife.com
